Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients
Abstract Background. Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients. Materials and Methods. This was an observational study enrolling HIV-1-infected, virologically suppressed patients switching to lamivudine plus dolutegravir.